
Pfizer Inc (NYSE:PFE) shares are trading higher Thursday. The company announced the acquisition of ReViral for a total consideration of up to $525 million.
ReViral has a portfolio of therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the respiratory syncytial virus (RSV) to the host cell. Sisunatovir has been granted Fast Track designation by the U.S. Food and Drug Administration.